Eli Lilly and Company

πŸ‡ΊπŸ‡ΈNew York Stock Exchange
Back to all articles
Eli Lilly and Company stock analysis LLY overview
Somewhat Bullish +45

Eli Lilly: Exceptional Pipeline, Less Attractive Entry Point (Rating Downgrade)

πŸ“ˆ Eli Lilly stock reached a 52-week high of $1,207.59 by the end of the first half of 2026.

πŸ’Š First-quarter sales for Alzheimer's drug Kisunla hit $124 million, up 490.5% year-over-year.

πŸš€ The rally is driven by strong performance in Mounjaro and the unprecedented efficacy of retatrutide for severe obesity.

⚠️ Analyst Allka Research downgraded LLY to a Hold rating due to sluggish demand for Omvoh.

πŸ’° The stock trades at a non-GAAP forward P/E ratio of 31.1x, cited as an unattractive entry point.

πŸ“Š Technical indicators show the stock trading above the +2Οƒ band formed from the VWAP after a small pullback.

πŸ† LLY is identified as a favorite within the $190 billion GLP-1 drugs market sector.

Bullish Signals
  • LLY stock reached a new 52-week high of $1,207.59, indicating strong recent momentum.
  • Kisunla generated $124 million in first-quarter sales, reflecting a massive 490.5% year-over-year growth.
  • The company's pipeline includes retatrutide, which is showing unprecedented efficacy in treating severe obesity.
  • Existing drugs Mounjaro and Kisunla are delivering strong performance that supports the recent rally.
  • LLY remains a top-ranked favorite within the massive $190 billion GLP-1 drugs market.
Risk Factors
  • Demand for the drug Omvoh is described as sluggish, acting as a drag on overall performance.
  • The stock trades at a non-GAAP forward P/E ratio of 31.1x, which an analyst considers an unattractive entry point.
  • An analyst has officially downgraded the rating from a previous bullish stance to Hold due to valuation concerns.
Full Analysis
Eli Lilly and Company (LLY) concluded the first half of 2026 with a significant rally, pushing its stock price to a 52-week high of $1,207.59. The primary drivers for this performance were the demonstrated efficacy of retatrutide in treating severe obesity and robust sales figures for existing drugs Mounjaro and Kisunla. Specifically, first-quarter revenue for Kisunla, the company's Alzheimer's medication, reached $124 million, representing a 490.5% year-over-year increase. Despite these strong operational metrics and LLY maintaining its status as a top performer in the $190 billion GLP-1 drugs market, an analyst from Allka Research has downgraded the stock rating to Hold. The downgrade is attributed to two main factors: sluggish demand for the drug Omvoh and the stock trading at a non-GAAP forward P/E ratio of 31.1x, which the analyst deems less attractive given the current valuation. Technical analysis notes that after a minor pullback, the stock remains trading above the +2Οƒ band formed from the VWAP. Consequently, while the pipeline and recent sales data remain exceptional, the combination of specific product headwinds and elevated valuation metrics has led to a more cautious outlook for investors looking at LLY as of June 26, 2026.